Mylan has been accused of underpaying Medicaid in rebates for EpiPens, and agreed to pay $465 million to the government to resolve such claims.
Mylan has been accused of underpaying Medicaid in rebates for EpiPens, and agreed to pay $465 million to the government to resolve such claims.